Objective: HIV protease inhibitors have been successfully used in highly active antiretroviral therapy of HIV-1 infection, but their benefits are compromised by a number of clinically important adverse side-effects. Several studies showed that protease inhibitors induce sarco/endoplasmic reticulum stress and overproduction of reactive oxygen species (ROS), but the hierarchy of these events was never established in protease inhibitor-treated cells. Our objective was to determine whether ROS production and sarco/endoplasmic reticulum stress were co-induced by protease inhibitors in human primary skeletal myotubes and whether antioxidant treatment with resveratrol could protect against protease inhibitor-induced cellular damages.
Introduction
HIV protease inhibitors have been successfully used in highly active antiretroviral therapy (HAART) of HIV-1 infection, the most effective treatment currently available. Incorporation of protease inhibitors in HAART has significantly reduced the morbidity and mortality and prolonged the lifespan of patients with HIV infection. Protease inhibitor benefits are unfortunately compromised by a number of clinically important adverse side-effects [1] . Most patients on HAART develop a metabolic syndrome associated with partial lipodystrophy, hyperlipidemia, insulin resistance, premature atherosclerosis and myocardial infarction [2] [3] [4] [5] [6] . Moreover, these patients face a growing number of other age-related comorbidities, such as neurodegeneration, osteopenia and malignancies [7, 8] . The cellular and molecular mechanisms underlying protease inhibitor-associated metabolic abnormalities remain elusive, but they seem to be related to overproduction of reactive oxygen species (ROS) [9] , induction of endoplasmic reticulum stress and activation of the unfolded protein response (UPR) [10, 11] .
In many cell models, such as pancreatic insulinoma cells, cultured vascular smooth muscle cells or fibroblasts, protease inhibitors induce intracellular ROS production that is prevented by cotreatment with the antioxidants thymoquinone [12] or N-acetyl cysteine [13] . In rat pancreatic insulinoma cells, a direct role of ROS in the inhibition of insulin secretion by nelfinavir is suggested because thymoquinone reverses the suppressive effect of nelfinavir [12] . However, the clear implication of oxidative stress in protease inhibitor-induced metabolic syndrome remains to be established. Protease inhibitors also affect the overall functions of endoplasmic reticulum compartments in human fibrosarcoma [14] and myeloma cells [14] and in mouse macrophages [15] . Specifically, they deplete endoplasmic reticulum calcium stores and induce endoplasmic reticulum stress leading to UPR activation and expression of the endoplasmic reticulum stress markers X-box binding protein 1 (XBP-1), activating transcription factor 4 (ATF-4) and C/EBP homologous protein (CHOP) [15] . These transcription factors operate as downstream components of UPR to protect endoplasmic reticulum against accumulation of unfolded/misfolded proteins (reviewed in [16] ). UPR hinders the accumulation of misfolded proteins in endoplasmic reticulum by facilitating the expression of endoplasmic reticulum chaperones, inhibiting protein entry into endoplasmic reticulum through mRNA translation arrest and by increasing the efficiency of the endoplasmic reticulum-associated machinery for protein degradation (ERAD) [16] . Sarcoplasmic reticulum and endoplasmic reticulum are crucial for proper folding and posttranscriptional modifications of many cell surface proteins, including lipid raft microdomains, which are important cell signaling platforms (reviewed in [17] ). In osteoclasts, recruitment of c-src and tumor necrosis factor (TNF) receptor-associated factor 6 (TARF-6) to lipid rafts is inhibited by ritonavir treatment through an unknown mechanism, which could be linked to endoplasmic reticulum stress [18] .
Whether protease inhibitors inhibit protein localization at lipid rafts in other tissues and how protease inhibitors lead to accumulation of unfolded/misfolded proteins in endoplasmic reticulum lumen remain important questions to be elucidated as well as the precise implication of ROS production in these deleterious processes. To elucidate these questions, we treated cultures of primary human myoblasts after they fused to form mature differentiated myotubes with the protease inhibitors atazanavir, lopinavir, ritonavir and saquinavir. Such treatment increased ROS production, modified sarco/ endoplasmic reticulum morphology and induced sarco/ endoplasmic reticulum stress in myotubes. Moreover, these protease inhibitors decreased the expression and localization at lipid rafts of Caveolin 3 and Flotillin 1, two major components of lipid raft microdomains [19] [20] [21] [22] . To evaluate the role of ROS production in these deleterious effects, we used the antioxidant resveratrol, a stilbene found naturally in various plants with the highest concentration in grape skin and peanuts [23, 24] . Resveratrol supplementation protects against ischemia/reperfusion injury [25] [26] [27] and attenuates many age-related illnesses [25, [28] [29] [30] , such as cardiovascular disease, various types of cancers, neurodegeneration and type II diabetes, making it a particularly attractive molecule to attenuate protease inhibitor-induced cellular damage. Following cotreatment with resveratrol, protease inhibitors' deleterious effects on myotubes were inhibited, suggesting that sarco/endoplasmic reticulum stress and lipid raft perturbation depend on ROS overproduction.
Methods
Reagents Saquinavir, ritonavir, lopinavir and atazanavir were purchased from Sequoia Research Products (Pangbourne, UK). Thapsigargin and resveratrol were purchased from Sigma-Aldrich (St. Quentin Fallavier, France), nitro blue tetrazolium (NBT) from Merck (Darmstadt, Germany) and CM-H2DCFDA derivatives [5 (and 6) chloromethyl-2 0 ,7 0 dichlorodihydrofluorescein diacetate, acetyl ester] from Invitrogen (Cergy Pontoise, France).
Anti-alpha tubulin monoclonal antibody (mAb) was from Sigma-Aldrich; anti-CHOP mAb was from Cell Signaling Technology (Ozyme, Montigny, France); antiBip/GRP78, Flotillin 1, Caveolin 3 were from BD Transduction Laboratories (Franklin Lakes, New Jersey, USA). The Alexa Fluor secondary antibodies were from Invitrogen (Cergy Pontoise, France).
Primary cell cultures
Primary human myoblasts were isolated as described previously [31] from quadriceps muscle biopsies obtained from the 'AFM-BTR Banque de Tissus pour la Recherche' (Hôpital de la Pitié-Salpêtrière, Paris). 30 000 myoblasts/ml were grown in Dulbecco's modified eagle medium (DMEM) (Cambrex, Lonza, Verviers, Belgium) supplemented with 10% fetal calf serum (FCS) (Perbio Science, Brebieres, France), 1% UltroserG (Biosepra CI Pherben, Cergy St. Christophe, France) and penicillin/streptomycin (Cambrex) for 5 days. At day 5, myoblasts started to fuse and cultures were switched to differentiation medium composed of DMEM supplemented with 10% FCS and penicillin/streptomycin for 4 days to obtain terminally differentiated myotubes that were then used for all the experiments. Protease inhibitors were dissolved in dimethyl sulfoxide (DMSO) with 0.05% bovine serum albumin (BSA) and the final concentration of DMSO in differentiation medium was less than 0.1%; resveratrol was dissolved in ethanol and the final concentration of ethanol in differentiation medium was less than 0.1%. In control, cells were incubated with DMSO and/or ethanol. Cell viability was assessed by measuring cellular ATP levels using the ATPLite luminescence assay (Perkin-Elmer, Courtaboeuf, France).
Reactive oxygen species production ROS production was detected by measuring NBT reduction. Cells were treated with protease inhibitors and 25 and 50 mmol/l resveratrol, or not, for 18 h before incubation with 0.2% NBT in DMEM for 90 min. Then cell extracts were prepared as described previously [32] and the amount of dark-blue reduced NBT in extracts in 50% acetic acid was assessed at 560 nm and the optical density values were normalized to protein concentration measured with the bicinchoninic acid assay. We also used CM-H2DCFDA as cell-permeant indicator for ROS. Myotubes were cultured in six-well plates, treated with protease inhibitors and 25 mmol/l resveratrol, or not, for 8 h, before being incubated with 5 mmol/l CM-H2DCFDA and DAPI in phosphate-buffered saline (PBS) at 378C in the dark for 60 min. Cells were then washed with PBS three times, fixed in 4% paraformaldehyde and stored at 48C for up to 16 h before image acquisition. Images were taken of at least 10 different regions with a Zeiss fluorescent microscope (AxioCamMRm equipped with a charged-coupled device camera Zeiss AxioCamMRm) and fluorescence quantification was performed using Image J (available at http:// www.rsb.nih.gov/ij/). All experiments were performed in triplicate.
Immunoblotting, immunofluorescence and electron microscopy Cell extracts prepared as described previously [31] were subjected to SDS-PAGE, blotted onto nitrocellulose membranes and probed with the indicated antibodies. Bound antibodies were detected with a chemiluminescence detection kit (Perkin-Elmer). Analysis and quantification were performed with Kodak 1D3.6 software. For immunofluorescence, cells were fixed in 4% paraformaldehyde in PBS and permeabilized with 0.1% Triton X-100 in PBS. Cells were incubated with primary antibodies for 2 h, followed by Alexa Fluor secondary antibodies and DAPI staining. Cell imaging was performed at the 'Centre Regional d'Imageries Cellulaire de Montpellier' with a Leica DM6000 microscope (Wetlar, Germany) using a 40x/1.30 EC Plan-Neofluar grade oil objective. Images were captured as 16 TIFF files with a Micro Max 1300 CCD camera (RS-Princeton Instruments Inc., Trenton, New Jersey, USA) driven by MetaMorph (version 7; Universal Imaging Corp, Downingtown, Pennsylvania, USA). Images were processed using ImageJ (National Institute of Health, Bethesda, Maryland, USA).
For ultrastructural evaluation, primary human myotubes were immersed in a solution of 3.5% glutaraldehyde in Sorensen's buffer (0.1 mol/l, pH 7.4) at 48C overnight. They were then rinsed in Sorensen's buffer and postfixed in 1% osmic acid and 0.8% potassium ferrocyanide in the dark and at room temperature for 2 h. After two rinses in Sorensen's buffer, cells were dehydrated in a graded series of ethanol solutions (30-100%) and then embedded in EmBed 812. Thin sections (85 nm; Leica-Reichert Ultracut E, Wetzlar, Germany) were cut at different levels of each block, counterstained with uranyl acetate and observed using a Hitachi 7100 transmission electron microscope at the Centre de Ressources en Imagerie Cellulaire de Montpellier (France).
Isolation of detergent-resistant membrane fractions Ten 10 cm dishes of myotubes were harvested, then centrifuged and cell pellets suspended in ice-cool lysis buffer containing 1% Triton X-100. After measurement of the total protein concentration with the bicinchoninic acid assay, cell extracts were fractionated on a 4-ml sucrose gradient [33] . Ten fractions were collected from the top. Thirty microliters of each fraction was analyzed by immunoblotting for Caveolin 3, Flotillin 1, tubulin a and actin beta expression.
Statistical analysis
All quantitative data are presented as mean AE SEM. Statistical analysis to determine significance was performed using the Student's t-test. Values of P less than or equal to 0.05 were considered significant.
Results
Resveratrol protects against protease inhibitorinduced production of reactive oxygen species in human myotubes As ROS induce cellular damage that could mediate protease inhibitor-mediated metabolic syndrome, ROS production was investigated in cultures of primary human myoblasts that fused in vitro to form mature differentiated myotubes. Myotubes were treated with four protease inhibitors (20 mmol/l atazanavir, 20 mmol/l lopinavir, 40 mmol/l ritonavir and 20 mmol/l saquinavir) for 18 h and ROS production was evaluated indirectly by measuring NBT reduction. ROS production was significantly increased in protease inhibitor-treated cells in comparison to untreated control cells (Fig. 1a) . Moreover, ROS production in protease inhibitor-treated myotubes was inhibited by co-incubation with resveratrol in a dose-dependent manner (Fig. 1a) , using noncytotoxic resveratrol concentrations (data not shown). These results were confirmed using the fluorescent probe CM-H2DCFDA. Dichlorofluorescein oxidation increased two-fold in myotubes treated with protease inhibitors for 8 h compared with control cells (Fig. 1b) and again this effect was significantly inhibited by antioxidant treatment with 25 mmol/l resveratrol (Fig. 1b) , suggesting that resveratrol could protect against ROS-mediated iatrogenic effects of protease inhibitors.
Resveratrol protects against protease inhibitorinduced sarco/endoplasmic reticulum stress in human myotubes Accumulation of Prelamin A following protease inhibitordependent inhibition of the endoplasmic reticulum metalloproteinase ZMPSTE24 was proposed to mediate protease inhibitor-associated iatrogenic effects in fibroblasts. Thus (Fig. 2a) , like in fibroblasts, but not in myotubes (Fig. 2a) , suggesting that protease inhibitor-induced iatrogenic effects are independent of Prelamin A accumulation in human myotubes. Next, we analyzed protease inhibitor effects on sarco/endoplasmic reticulum integrity because ROS can alter cellular redox reactions that interfere with protein disulfide bonding and result in protein misfolding leading to sarcoplasmic stress and UPR activation (reviewed in [16] ). Following incubation with atazanavir, lopinavir, ritonavir and saquinavir (same concentrations as before) and 25 mmol/l resveratrol, or not, sarco/endoplasmic reticulum distribution was monitored by immunodetection of BiP, a major endoplasmic reticulum chaperone protein and by high-resolution electron microscopy. In untreated myotubes, BiP was detected in the entire cell confirming the broad distribution of sarco/endoplasmic reticulum (Fig. 2b) and electron microscopy showed the typical sarco/endoplasmic reticulum morphology as flattened sacs (Fig. 2c) . In myotubes treated with protease inhibitors for 18 h or with 100 nmol/l of thapsigargin, an irreversible inhibitor of the endoplasmic reticulum Ca 2þ -ATPase that induces sarco/endoplasmic reticulum stress, for 4 h (Fig. 2b  and c) , the broad expression of BiP was lost. Moreover, sarco/endoplasmic reticulum vacuolization, observed in the immunofluorescence images (arrows in Fig. 2b ; addition of arrows will facilitate reading), was confirmed by electron microscopy (arrows in Fig. 2c ). On the contrary, co-incubation with resveratrol protected against protease inhibitor-induced sarco/endoplasmic reticulum morphological alterations (Fig. 2b and c) , suggesting that they, at least in part, are due to ROS overproduction.
We next tested whether protease inhibitors could induce sarco/endoplasmic reticulum stress and activate UPR in human myotubes. To this aim, myotubes were incubated with protease inhibitors for 18 h and with thapsigargin for 4 h. Expression of CHOP, which is a key downstream transcription factor of UPR activated during sarco/ endoplasmic reticulum stress (Fig. 3a) , strongly increased in thapsigargin-treated and protease inhibitor-treated myotubes. Co-incubation with 25 mmol/l resveratrol (Fig. 3b) , however, inhibited CHOP upregulation in protease inhibitor-treated myotubes (from 80-90% of CHOP-positive nuclei to 9-13%). Thus, induction of sarco/endoplasmic reticulum stress by protease inhibitors is hindered by resveratrol. 
Resveratrol protects against protease inhibitordependent inhibition of Caveolin 3 and Flotillin 1 expression and localization to lipid rafts
In an initial step to reestablish homeostasis and normal sarco/endoplasmic reticulum function, UPR leads to the export of unfolded or misfolded sarco/endoplasmic reticulum proteins to the cytosol for degradation. As sarco/endoplasmic reticulum is crucial for proper folding and posttranscriptional modifications of many cell surface proteins, including lipid raft microdomains, which are Resveratrol and PI-induced side-effects Touzet and Philips 1441 (Fig. 4a for atazanavir and data not shown for the other protease inhibitors). Moreover, this decrease was dose-dependent and timedependent in human myotubes and was obtained at therapeutic concentrations (Fig. 4b) . As for the previously described protease inhibitor effects, cotreatment with different concentrations (from 5 to 25 mmol/l) of resveratrol for 18 h inhibited reduction of Caveolin 3 expression in myotubes in a dose-dependent manner ( Fig. 4c and d) .
To determine whether protease inhibitors also affected Caveolin 3 and Flotillin 1 localization at lipid raft microdomains, Triton X-100 lysates of human myotubes, which had been treated with 20 mmol/l of atazanavir and
Resveratrol and PI-induced side-effects Touzet and Philips 1443 25 mmol/l of resveratrol (or not), were fractionated on sucrose density gradients. Buoyant density and resistance to solubilization by Triton X-100 at 48C are widely used to isolate raft membranes. In these preparations, Caveolin 3 and Flotillin 1 retain their association with lipids and are frequently used as lipid raft markers. Indeed, they strongly accumulated in fractions 3-5 (lipid raft fractions) of control cells (DMSO alone) (Fig. 5a ), but less in those of atazanavir-treated myotubes (Fig. 5a) . Again, resveratrol reduced this protease inhibitor effect (Fig. 5a ). Western blot analysis of pooled fractions 3-5 (lipid raft fractions) and pooled fractions 8-10 (no raft fractions) (Fig. 5b) confirmed that localization of Caveolin 3 and Flotillin 1 at lipid rafts was impaired in myotubes treated with atazanavir, lopinavir, ritonavir and saquinavir and that this protease inhibitor effect was hindered by resveratrol (Fig. 5b) . These results indicate that protease inhibitors decrease the expression and membrane localization of two important components of lipid raft microdomains. Moreover, resveratrol protects against protease inhibitor-induced loss of these proteins in lipid raft microdomains, suggesting that this antioxidant could attenuate protease inhibitor-mediated iatrogenic effects.
Discussion
In this work, we show that protease inhibitor treatment induces ROS production, sarco/endoplasmic reticulum damage, sarcoplasmic stress and reduces Caveolin 3 and Flotillin 1 localization at lipid rafts. Cotreatment with the antioxidant resveratrol protects against these effects.
Our results suggest that, at least in myotubes, protease inhibitor side-effects are not due to defects in Prelamin A conversion. A role for Lamin A/C metabolism in protease inhibitor-associated metabolic/lipodystrophy syndrome and premature ageing was proposed because protease inhibitors block the zinc metalloproteinase ZMPSTE24, an endoplasmic reticulum protein localized at the cytosolic surface of endoplasmic reticulum membranes, thus causing accumulation of farnesylated Prelamin A [34] [35] [36] . Retention of the farnesylated residue confers toxic properties to the partially processed Prelamin A [37] [38] [39] and genetic defects in the conversion of Prelamin A to mature Lamin A (e.g., ZMPSTE24 deficiency) cause lipodystrophy and premature ageing syndromes, including the Hutchinson-Gilford progeria syndrome [40] [41] [42] . However, our results suggest that, at least in myotubes, protease inhibitor side-effects are due to another mechanism.
Our work indicates that ROS overproduction, sarco/ endoplasmic reticulum stress and lipid raft perturbation were co-induced by protease inhibitor treatment in human primary myotubes. The deleterious effects of HIV protease inhibitors had been previously associated with ROS overproduction and endoplasmic reticulum stress, but the hierarchy between these two events was not known. In human aortic endothelial cells, protease inhibitors alone and as part of HAART regimens increase ROS production [9] . Nelfinavir induces oxidative stress and can also lead to adipocyte necrosis [43] and premature senescence in human fibroblasts [34] . The clear implication of oxidative stress in protease inhibitorinduced cellular damages is demonstrated by cotreatment with antioxidants. In 3T3-L1 adipocytes, the superoxide dismutase-mimetic antioxidant MnTBAP protects against nelfinavir-induced insulin resistance and cleavage of poly-ADP ribose polymerase, a marker of apoptosis [13] . In rat pancreatic insulinoma cells, nelfinavir-dependent inhibition of glucose-stimulated insulin secretion is prevented by thymoquinone [12] , a component of black seed oil with potent antioxidant properties. Similarly, we show that atazanavir, lopinavir, ritonavir and saquinavir induce ROS overproduction and sarco/endoplasmic reticulum stress (sarco/endoplasmic reticulum swelling, CHOP expression and loss of Caveolin 3 and Flotillin 1 expression) in differentiated myotubes. Induction of endoplasmic reticulum stress by protease inhibitors was already shown in cancer cell lines [10, 11, 14] and in macrophages [15] , but the potential implication of ROS production on the induction of endoplasmic reticulum stress was not investigated in these studies. Our results clearly suggest that protease inhibitor-induced sarco/ endoplasmic reticulum stress and UPR are mediated by ROS overproduction because the antioxidant resveratrol protects against sarco/endoplasmic reticulum swelling, CHOP upregulation and loss of Caveolin 3 and Flotillin 1 expression.
Protease inhibitor-induced oxidative stress could induce sarco/endoplasmic reticulum stress through different mechanisms. Nitric oxide and other ROS may modify oxidizable residues (cysteine, tyrosine) of sarcoplasmicassociated calcium channels, such as RyR (S-nitrosylation) and sarco/endoplasmic reticulum Ca 2þ ATPases (by tyrosine nitration) leading to sarco/endoplasmic reticulum calcium depletion, which is a cause of protein misfolding [44] [45] [46] and consequently of sarco/endoplasmic reticulum stress. Such mechanism could explain how ritonavir, atazanavir and indinavir decreased endoplasmic reticulum calcium content in a dosedependent manner in mouse macrophages [15] . In addition, production of nitric oxide, a mediator of protein nitrosylation, and other ROS that alter cellular redox-dependent reactions interferes with protein disulphide bonding and results in misfolding of proteins that accumulate in endoplasmic reticulum lumen [47] . Interestingly, our results show that protease inhibitors inhibit localization of Caveolin 3 and Flotillin 1 at lipid raft microdomains. These two proteins are palmitoylated on cysteine residues in association with the endoplasmic reticulum and this posttranslational modification is needed for their localization at lipid rafts microdomains (reviewed in [19, 48] ). Caveolin 3 and Flotillin 1 are two major components of lipid rafts and are implicated in insulin signaling to trigger glucose transporter redistribution in adipocytes and myotubes [49] . Thus, inhibition of their recruitment to lipid rafts by protease inhibitors could play an important role in protease inhibitor-induced insulin resistance. The protease inhibitor effect on lipid rafts is not restricted to myotubes and it has been described also in osteoclast precursors [18] . Ritonavir blocks osteoclastogenesis and osteoclast function by disrupting the recruitment of TARF6/c-Src complex to lipid rafts by an unidentified mechanism [18] . In myotubes, resveratrol protects against degradation and mislocalization of Caveolin 3 and Flotillin 1 induced by protease inhibitors, suggesting that these cellular damages are mediated by sarco/ endoplasmic reticulum stress and oxidative stress. Resveratrol holds a number of reported health benefits (cardioprotective, antiaging, neuroprotective, antiviral and anticancer) [25] [26] [27] [28] [29] [30] that make of it a particularly attractive molecule to attenuate protease inhibitorinduced side-effects.
Using the antioxidant resveratrol, we show that inhibition of protease inhibitor-induced ROS overproduction protects against protease inhibitor-induced sarco/endoplasmic reticulum stress and mislocalization of lipid raft proteins in human myotubes. These results strongly suggest that resveratrol treatment may be used as a potential therapeutic agent to attenuate protease inhibitor-induced side-effects.
